Chemistry:Glycerol phenylbutyrate
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.661 g·mol−1 |
3D model (JSmol) | |
| |
|
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[2] It is an FDA-approved prescription drug in the US.[3] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.[4]
Society and culture
Economics
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[5]
References
- ↑ "Ravicti- glycerol phenylbutyrate liquid". 13 September 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=900e7dc0-9afe-4f50-80de-90567bb78519.
- ↑ "FDA approves new drug for the chronic management of some urea cycle disorders" (Press release). U.S. Food and Drug Administration. 1 February 2013. Archived from the original on 2013-03-07. Retrieved 2013-04-01.
- ↑ "FDA Approved Drug Products: Ravicti". Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203284.
- ↑ "Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada". Journal of Law and the Biosciences 3 (1): 158–166. April 2016. doi:10.1093/jlb/lsv060. PMID 27774236.
- ↑ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". Genetic Engineering & Biotechnology News. 30 March 2015. http://www.genengnews.com/gen-news-highlights/horizon-pharma-to-acquire-hyperion-therapeutics-for-1-1b/81251089/.
Original source: https://en.wikipedia.org/wiki/Glycerol phenylbutyrate.
Read more |